P/E ratio for PTC Therapeutics (PTCT)
P/E ratio as of April 2024 (TTM): -2.97
According to PTC Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.96879. At the end of 2022 the company had a P/E ratio of -4.90.
P/E ratio history for PTC Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.90 | -8.6% |
| 2021 | -5.36 | -41.41% |
| 2020 | -9.15 | -14.84% |
| 2019 | -10.7 | -15.78% |
| 2018 | -12.8 | 59.1% |
| 2017 | -8.02 | 206.51% |
| 2016 | -2.62 | -59.14% |
| 2015 | -6.40 | -60.3% |
| 2014 | -16.1 | 166.28% |
| 2013 | -6.06 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 25.2 | -950.29% | 🇨🇭 Switzerland |
 Vertex Pharmaceuticals VRTX | 30.4 | -1,122.50% | 🇺🇸 USA |
 Xencor XNCR | -9.40 | 216.53% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -15.1 | 408.95% | 🇺🇸 USA |
 Fate Therapeutics
FATE | -2.60 | -12.45% | 🇺🇸 USA |
 Avidity Biosciences RNA | -7.71 | 159.80% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.